Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritis
ИММУНОГЕННОСТЬ ПОЛИСАХАРИДНОЙ ПНЕВМОКОККОВОЙ ВАКЦИНЫ У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ
Batozhargalova B.Ts. Sagatbayeva N.A. Abdullayeva G.M. Bytyrkhanov Sh.K. Soloveva I.L. Kostinov M.P. Shmitko A.D.
2024Interregional public organization Association of infectious disease specialists of Saint-Petersburg and Leningrad region (IPO AIDSSPbR)
Jurnal Infektologii
2024#16Issue 336 - 44 pp.
The presented review searched for articles in the databases PubMed, Web of Science, Scopus, Google Scholar, eLibrary (2002-2022) and assessed the immunogenicity of the 23-valent polysaccharide pneumococcal vaccine (PPV23) in adult patients with rheumatoid arthritis (RA), receiving various antirheumatic drugs. The results of this review indicated sufficient immunogenicity of PPV23 in RA patients receiving monotherapy with various biological drugs (bDMARDs) (TNFα inhibitors, IL6 receptor inhibitors, T-lymphocyte co-stimulation blockers), targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), and glucocorticoids (GC) in medium and low doses. Monotherapy with methotrexate (MTX), rituximab and combination therapy with bDMARDs +MTX, tsDMARDs+MTX in RA patients reduced the post-vaccination pneumococcal response. IgG AT generated in response to PPV23 injection shown functional activity even in RA patients whose antibodies were either lowered in patients receiving MTX or were not detectable at protective values following bDMARD therapy. The potential for pneumococcus antibody production in RA patients receiving therapy with disease-modifying antirheumatic drugs (DMARDs), tsDMARDs and bDMARDs, was concluded. Vaccination against pneumococcal infection should be advised prior to starting therapy due to the likelihood of low antibody levels developing during rituximab treatment.
23-valent polysaccharide pneumococcal vaccine , immunogenicity , rheumatoid arthritis , therapy
Text of the article Перейти на текст статьи
Research Institute of Vaccines and Sera named after I.I. Mechnikov, Moscow, Russian Federation
Kazakh National Medical University named after S.D. Asfendivarov, Almaty, Kazakhstan
Ulyanovsk State University, Ulyanovsk, Russian Federation
First Moscow State Medical University named after I.M. Sechenov, Sechenov University, Moscow, Russian Federation
Research Institute of Vaccines and Sera named after I.I. Mechnikov
Kazakh National Medical University named after S.D. Asfendivarov
Ulyanovsk State University
First Moscow State Medical University named after I.M. Sechenov
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026